Frequently Asked Questions
What is Catalyst and when did it launch?
Stanford Medicine Catalyst was founded in 2020 to help faculty and inventors across Stanford University translate their ideas into transformative health innovations.
We aim to help inventors and entrepreneurs pilot their ideas through clinical implementation and then, if required, spin them out into companies to maximize their impact.
What sort of innovations are you looking for?
We are looking for ideas across four main verticals: diagnostics, therapeutics, medical technology, and digital health. A few examples include innovative approaches to early detection, patient care, or care delivery here at Stanford and beyond.
The application for our 2022 cohort is now closed. Please check back soon for the dates of our 2023 cohort.
Who can apply and what is the process?
We like to hear ideas from everyone at Stanford including faculty, staff, and students. We are looking for entrepreneurial teams interested in deploying innovations and executing on their ideas.
Once our current application cycle closes on December 5th, teams of Stanford Medicine faculty and clinical experts, as well as partners in the investment community, will rate submissions and select the most promising innovations. Our team will work with those selected to assess next steps in advancing the innovation with varying levels of support.
What might my team receive by applying to Catalyst?
Successful teams will receive support in a variety of forms: financial, of course, but more importantly, teams will receive mentorship, connections to industry veterans and investors as appropriate, help with enterprise-level deployment including regulatory and manufacturing guidance, or appropriate digital deployment. These forms of additional support differentiate the Catalyst Program from a research grant and mean that the Catalyst team works closely with you every step of the way.
We also look to pilot and implement innovations within Stanford Medicine clinical settings. We aim to advance from prototype to execution or from beta to production supported application as quickly as possible, enabling impact for Stanford patients immediately and scaling beyond Stanford as soon as possible.